Your browser doesn't support javascript.
Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021.
Bradley, Marie C; Perez-Vilar, Silvia; Chillarige, Yoganand; Dong, Diane; Martinez, Ashley I; Weckstein, Andrew R; Dal Pan, Gerald J.
  • Bradley MC; Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland.
  • Perez-Vilar S; Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland.
  • Chillarige Y; Acumen LLC, Burlingame, California.
  • Dong D; Department of Veterans Affairs Center for Medication Safety, Hines, Illinois.
  • Martinez AI; Department of Population Medicine, Harvard Medical School, Boston, Massachusetts.
  • Weckstein AR; Aetion Inc, New York, New York.
  • Dal Pan GJ; Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland.
JAMA ; 327(20): 2015-2018, 2022 05 24.
Article in English | MEDLINE | ID: covidwho-1888451
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Glucocorticoids Type of study: Observational study Limits: Humans Country/Region as subject: North America Language: English Journal: JAMA Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Glucocorticoids Type of study: Observational study Limits: Humans Country/Region as subject: North America Language: English Journal: JAMA Year: 2022 Document Type: Article